Market Overview:
The global metastatic breast cancer treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of breast cancer, technological advancements in the field of metastatic breast cancer treatment, and rising awareness about metastatic breast cancer. Based on type, the global metastatic breast cancer treatment market is segmented into chemotherapy, radiation therapy, biologic targeted therapy, and surgery (breast surgery and hormone therapy). The chemotherapy segment is expected to dominate the global market during the forecast period owing to its high adoption rate for treating various types of cancers including metastatic breast cancer. Based on application, the hospitals segment is expected to account for a major share of the global market during the forecast period. This can be attributed to increasing number of hospitals offering advanced treatments for patients with metastatic breast cancer.
Product Definition:
Metastatic breast cancer is a stage four breast cancer that has spread to other parts of the body, such as the lungs, bones, or brain. Treatment for metastatic breast cancer typically includes a combination of chemotherapy, radiation therapy, and hormonal therapy. Metastatic breast cancer treatment is important because it can help prolong life and improve quality of life for patients.
Chemotherapy:
Chemotherapy is a group of drugs or medical treatment used to treat cancer. The major goal of chemotherapy is to kill all the cancer cells, so that the disease cannot grow any further. There are two types of chemotherapies: first-line and second-line therapies. First-line therapies include 5-ALA, Adcetris, Avastin (bevacizumab), and Emend (olumacostat).
Radiation Therapy:
Radiation therapy is a form of treatment that uses high energy waves to cure cancer. The radiation oncologists or radiotherapists direct the beam at the exact area where the cancer is growing. Radiation therapy can be used in combination with chemotherapy, surgery, and immunotherapy for treating various types of cancers such as breast cancer, prostate cancer, head & neck cancers and others.
Application Insights:
The other application segment includes metastatic hormone-receptor-positive breast cancer treatment, metastatic prostate cancer treatment, and others. The market for metastic hormone receptor positive breast cancer is anticipated to be dominated by the hospital application segment owing to the increasing number of hospitals offering advanced care facilities in various countries such as Germany, U.K., Japan and China. In addition, a rise in healthcare expenditure along with an increase in the geriatric population prone to developing this disease is expected to propel growth during the forecast period.
Hospital applications are also estimated to have significant growth over the forecast period due largely on a rise in government funding for research & development activities pertaining specifically towards metastatic breast cancers at large tertiary care centers across North America and Europe coupled with high prevalence of this disease across these regions which has resulted in increased demand for advanced treatments resulting primarily from chemotherapy or radiation therapy administered at larger centers thus driving overall market growth during future years.
Regional Analysis:
North America dominated the global metastatic breast cancer treatment market in 2017. This can be attributed to the presence of a large number of key players, high adoption rate for novel therapies, and favorable reimbursement policies. In addition, increasing awareness about early diagnosis is contributing to market growth in this region. According to Breastcancer.org statistics published in 2018, around 2 million women are diagnosed with invasive breast cancer every year in U.S., and 1 out of 8 deaths occur due to breast cancer each year in U.S., making it one of the leading causes for death among women between 40 and 59 years old across the globe (1). Such alarming statistics have led researchers & doctors from across North America come together as part of “WE ARE THE CHANGE†initiative organized by Susan G Komen Foundation that aims at eradicating this disease altogether by 2025 (2).
Growth Factors:
- Increasing incidence of breast cancer
- Growing awareness about metastatic breast cancer treatment options
- Rising demand for better and more effective treatments
- Technological advancements in the field of metastatic breast cancer treatment
- Availability of government funding and support for research and development
Scope Of The Report
Report Attributes
Report Details
Report Title
Metastatic Breast Cancer Treatment Market Research Report
By Type
Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy
By Application
Hospitals, Clinics, Other
By Companies
Roche, Novartis, Merck, Eli Lilly, Johnson & Johnson, Pfizer, AstraZeneca, GlaxoSmithKline, Sun Pharmaceutical, Bayer, Gilead Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
159
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Metastatic Breast Cancer Treatment Market Report Segments:
The global Metastatic Breast Cancer Treatment market is segmented on the basis of:
Types
Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Novartis
- Merck
- Eli Lilly
- Johnson & Johnson
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sun Pharmaceutical
- Bayer
- Gilead Sciences
Highlights of The Metastatic Breast Cancer Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Radiation Therapy
- Biologic Targeted Therapy
- Breast Surgery
- Hormone Therapy
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metastatic Breast Cancer Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metastatic breast cancer is cancer that has spread from the original tumor to other parts of the body. Treatment typically includes surgery, chemotherapy, and radiation therapy.
Some of the key players operating in the metastatic breast cancer treatment market are Roche, Novartis, Merck, Eli Lilly, Johnson & Johnson, Pfizer, AstraZeneca, GlaxoSmithKline, Sun Pharmaceutical, Bayer, Gilead Sciences.
The metastatic breast cancer treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metastatic Breast Cancer Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metastatic Breast Cancer Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metastatic Breast Cancer Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metastatic Breast Cancer Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metastatic Breast Cancer Treatment Market Size & Forecast, 2020-2028
4.5.1 Metastatic Breast Cancer Treatment Market Size and Y-o-Y Growth
4.5.2 Metastatic Breast Cancer Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Radiation Therapy
5.2.3 Biologic Targeted Therapy
5.2.4 Breast Surgery
5.2.5 Hormone Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metastatic Breast Cancer Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metastatic Breast Cancer Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Radiation Therapy
9.6.3 Biologic Targeted Therapy
9.6.4 Breast Surgery
9.6.5 Hormone Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Radiation Therapy
10.6.3 Biologic Targeted Therapy
10.6.4 Breast Surgery
10.6.5 Hormone Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Radiation Therapy
11.6.3 Biologic Targeted Therapy
11.6.4 Breast Surgery
11.6.5 Hormone Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Radiation Therapy
12.6.3 Biologic Targeted Therapy
12.6.4 Breast Surgery
12.6.5 Hormone Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Radiation Therapy
13.6.3 Biologic Targeted Therapy
13.6.4 Breast Surgery
13.6.5 Hormone Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metastatic Breast Cancer Treatment Market: Competitive Dashboard
14.2 Global Metastatic Breast Cancer Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Novartis
14.3.3 Merck
14.3.4 Eli Lilly
14.3.5 Johnson & Johnson
14.3.6 Pfizer
14.3.7 AstraZeneca
14.3.8 GlaxoSmithKline
14.3.9 Sun Pharmaceutical
14.3.10 Bayer
14.3.11 Gilead Sciences
